Even though it was a small study of only 19 participants suffering from rectal cancer, researchers are optimistic about an experimental cancer drug called dostarlimab, which allowed the patient’s own immune system to target and distort cancer cells — all without the use of chemotherapy, radiation, or surgery.
Dostarlimab is a monoclonal antibody sold under the brand name Jemperli. It was was approved for medical use in the United States and the European Union in April 2021.
>>Read more about the cancer trial HERE.
